Jim Cramer - Mad Money Regeneron Pharmaceuticals Inc REGN-Q BUY Jun 14, 2024

Trades at 19x earnings, but have a huge drug pipeline.

Shares are down in the past 24 hours due to a delay in a drug approval. But another drug remains strong in sales, and they have double-digit in oncology drugs in trials. A great science company.

A quality company. Trades at 17x. The FDA is delaying approval of a drug, but that is correctable because the issue isn't about safety or efficacy.

The momentum is waning, and last quarter revenue growth was only 14%. They're coming to the end of the road.

An analyst upgraded this to $1,025, a very long way to go. He's gained 40% in this himself. It's reasonable at a 24x PE and enjoys momentum. Sees nothing to derail this.

Are showcasing their key drugs next week, but he remains focused on their obesity drug candidate. It's still early in those test results.

It's had bad news this week, but it rarely gets a pull back. Long term this is fine.

Run by a fine CEO. Shares are up long term, and they have a lot of promising drugs in their pipeline, including one in weight-loss.

It's lost a third of its market cap and the selling is overdone. Now, is a buying opportunity.